One sizable US IPO is currently scheduled for the week ahead, along with a notable closed-end fund. In a typical year, companies would have just one more week to launch their offerings before the IPO market breaks for the summer. China-based Londian Wason New...read more
Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
Danneskjold and Galt Acquisition, a blank check company targeting fintech and AI, filed on Friday with the SEC to raise up to $150 million in an initial public offering. The company plans to raise $150 million by offering 15 million units at $10. Each unit...read more
US IPO Week Ahead: Chinese copper foil and last call for the summer IPO market
One sizable US IPO is currently scheduled for the week ahead, along with a notable closed-end fund. In a typical year, companies would have just one more week to launch their offerings before the IPO market breaks for the summer. China-based Londian Wason New...read more
US IPO Weekly Recap: August kicks off with flurry of biotech IPOs
Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
SPAC Danneskjold and Galt Acquisition files for a $150 million IPO, targeting fintech and AI
Danneskjold and Galt Acquisition, a blank check company targeting fintech and AI, filed on Friday with the SEC to raise up to $150 million in an initial public offering. The company plans to raise $150 million by offering 15 million units at $10. Each unit...read more